Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(12):1652–1654. doi: 10.1038/bjc.1997.612

Breast cancer: further metabolic-endocrine risk markers?

B A Stoll 1
PMCID: PMC2228209  PMID: 9413957

Abstract

There is evidence that increased oestrogen receptor (ER) expression in normal mammary epithelium may be a risk marker for the development of breast cancer. Insulin-like growth factor 1 (IGF1) is a potent inducer of mitosis and has been shown to synergize with oestrogen in stimulating the growth of human breast cancer in vitro. In these cells oestradiol has been shown to upregulate IGF type 1 receptor (IGFR), and recently a similar effect has been reported in normal human breast tissue xenografts in vivo. It has been postulated that the combined effect of oestradiol and IGF1 may stimulate proliferation in normal mammary epithelium and increase breast cancer risk. The bioavailability of IGF1 to the tissues is modulated by IGF-binding proteins (IGFBPs), and higher circulating levels of IGF1 and lower levels of IGFBP3 have been reported in breast cancer patients. Breast cancer specimens show a positive correlation between ER status and IGF receptor status, and also a negative correlation between ER status and IGFBP3 expression. Finally, ectopic growth hormone expression has been shown in a majority of specimens of normal and malignant breast tissue, and this may contribute to breast cancer risk, possibly by increasing the local level of bioavailable IGF1. Expansion of such findings may provide clinically useful markers of increased risk to breast cancer in women.

Full text

PDF
1652

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bershtein L. M., Bobrov Iu F., Ostroumova M. N., Kovalenko I. G., Lemekhov V. G. Sviaz' lipidemii i insulinemii s soderzhaniem zhira v tele, poverkhnost'iu tela i sostoianiem podkozhnoi zhirovoi tkani u bol'nykh rakom molochnoi zhelezy i legkogo. Vopr Onkol. 1985;31(1):44–51. [PubMed] [Google Scholar]
  2. Bruning P. F., Bonfrèr J. M., van Noord P. A., Hart A. A., de Jong-Bakker M., Nooijen W. J. Insulin resistance and breast-cancer risk. Int J Cancer. 1992 Oct 21;52(4):511–516. doi: 10.1002/ijc.2910520402. [DOI] [PubMed] [Google Scholar]
  3. Bruning P. F., Van Doorn J., Bonfrèr J. M., Van Noord P. A., Korse C. M., Linders T. C., Hart A. A. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer. 1995 Jul 28;62(3):266–270. doi: 10.1002/ijc.2910620306. [DOI] [PubMed] [Google Scholar]
  4. Chaudhuri B., Crist K. A., Mucci S., Malafa M., Chaudhuri P. K. Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery. 1993 Feb;113(2):134–137. [PubMed] [Google Scholar]
  5. Clarke R. B., Howell A., Anderson E. Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer. 1997;75(2):251–257. doi: 10.1038/bjc.1997.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Copeland G. P., Leinster S. J., Davis J. C., Hipkin L. J. Insulin resistance in patients with colorectal cancer. Br J Surg. 1987 Nov;74(11):1031–1035. doi: 10.1002/bjs.1800741124. [DOI] [PubMed] [Google Scholar]
  7. Daniell H. W. The influence of obesity and age at diagnosis on the estrogen receptor status of breast cancers. Perimenopausal predominance of estrogen receptor negative tumors. Cancer. 1988 Mar 15;61(6):1237–1240. doi: 10.1002/1097-0142(19880315)61:6<1237::aid-cncr2820610630>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  8. Darendeliler F., Hindmarsh P. C., Preece M. A., Cox L., Brook C. G. Growth hormone increases rate of pubertal maturation. Acta Endocrinol (Copenh) 1990 Mar;122(3):414–416. doi: 10.1530/acta.0.1220414. [DOI] [PubMed] [Google Scholar]
  9. Drafta D., Prişcu A., Neacşu E., Gangură M., Schindler A. E., Stroe E., Anghel C., Panaitescu G. Estradiol and progesterone receptor levels in human breast cancer in relation to cytosol and plasma estrogen level. J Steroid Biochem. 1983 Apr;18(4):459–463. doi: 10.1016/0022-4731(83)90066-3. [DOI] [PubMed] [Google Scholar]
  10. Ellis M. J., Singer C., Hornby A., Rasmussen A., Cullen K. J. Insulin-like growth factor mediated stromal-epithelial interactions in human breast cancer. Breast Cancer Res Treat. 1994;31(2-3):249–261. doi: 10.1007/BF00666158. [DOI] [PubMed] [Google Scholar]
  11. Favoni R. E., de Cupis A., Perrotta A., Sforzini S., Amoroso D., Pensa F., Miglietta L. Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status. J Cancer Res Clin Oncol. 1995;121(11):674–682. doi: 10.1007/BF01218526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Feldman M., Ruan W., Cunningham B. C., Wells J. A., Kleinberg D. L. Evidence that the growth hormone receptor mediates differentiation and development of the mammary gland. Endocrinology. 1993 Oct;133(4):1602–1608. doi: 10.1210/endo.133.4.8404600. [DOI] [PubMed] [Google Scholar]
  13. Foekens J. A., Portengen H., Janssen M., Klijn J. G. Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer. 1989 Jun 1;63(11):2139–2147. doi: 10.1002/1097-0142(19890601)63:11<2139::aid-cncr2820631112>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  14. Frost V. J., Helle S. I., Lønning P. E., van der Stappen J. W., Holly J. M. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab. 1996 Jun;81(6):2216–2221. doi: 10.1210/jcem.81.6.8964854. [DOI] [PubMed] [Google Scholar]
  15. Giovannucci E. Insulin and colon cancer. Cancer Causes Control. 1995 Mar;6(2):164–179. doi: 10.1007/BF00052777. [DOI] [PubMed] [Google Scholar]
  16. Giudice L. C. IGF binding protein-3 protease regulation: how sweet it is! J Clin Endocrinol Metab. 1995 Aug;80(8):2279–2281. doi: 10.1210/jcem.80.8.7543109. [DOI] [PubMed] [Google Scholar]
  17. Heslin M. J., Newman E., Wolf R. F., Pisters P. W., Brennan M. F. Effect of systemic hyperinsulinemia in cancer patients. Cancer Res. 1992 Jul 15;52(14):3845–3850. [PubMed] [Google Scholar]
  18. Holly J. M. The physiological role of IGFBP-1. Acta Endocrinol (Copenh) 1991;124 (Suppl 2):55–62. [PubMed] [Google Scholar]
  19. Jacquemier J. D., Hassoun J., Torrente M., Martin P. M. Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages--immunohistochemical study of 107 cases. Breast Cancer Res Treat. 1990 Feb;15(2):109–117. doi: 10.1007/BF01810783. [DOI] [PubMed] [Google Scholar]
  20. Juul A., Main K., Blum W. F., Lindholm J., Ranke M. B., Skakkebaek N. E. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994 Jul;41(1):85–93. doi: 10.1111/j.1365-2265.1994.tb03788.x. [DOI] [PubMed] [Google Scholar]
  21. Khan S. A., Rogers M. A., Obando J. A., Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res. 1994 Feb 15;54(4):993–997. [PubMed] [Google Scholar]
  22. Kleinberg D. L., Ruan W., Catanese V., Newman C. B., Feldman M. Non-lactogenic effects of growth hormone on growth and insulin-like growth factor-I messenger ribonucleic acid of rat mammary gland. Endocrinology. 1990 Jun;126(6):3274–3276. doi: 10.1210/endo-126-6-3274. [DOI] [PubMed] [Google Scholar]
  23. Markopoulos C., Berger U., Wilson P., Gazet J. C., Coombes R. C. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J (Clin Res Ed) 1988 May 14;296(6633):1349–1351. doi: 10.1136/bmj.296.6633.1349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Matsumoto K., Sakamoto G., Nomura Y. International comparisons concerning breast cancer and steroid receptors. Anticancer Res. 1986 Jul-Aug;6(4):621–624. [PubMed] [Google Scholar]
  25. McGuire S. E., Hilsenbeck S. G., Figueroa J. A., Jackson J. G., Yee D. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett. 1994 Feb 28;77(1):25–32. doi: 10.1016/0304-3835(94)90343-3. [DOI] [PubMed] [Google Scholar]
  26. Mehta R. R., Hart G., Das Gupta T. K. Steroid receptors in breast cancer patients. Influence of obesity and age at diagnosis. Anticancer Res. 1992 Jul-Aug;12(4):1311–1314. [PubMed] [Google Scholar]
  27. Mol J. A., Henzen-Logmans S. C., Hageman P., Misdorp W., Blankenstein M. A., Rijnberk A. Expression of the gene encoding growth hormone in the human mammary gland. J Clin Endocrinol Metab. 1995 Oct;80(10):3094–3096. doi: 10.1210/jcem.80.10.7559904. [DOI] [PubMed] [Google Scholar]
  28. Papa V., Gliozzo B., Clark G. M., McGuire W. L., Moore D., Fujita-Yamaguchi Y., Vigneri R., Goldfine I. D., Pezzino V. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 1993 Aug 15;53(16):3736–3740. [PubMed] [Google Scholar]
  29. Pekonen F., Partanen S., Mäkinen T., Rutanen E. M. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res. 1988 Mar 1;48(5):1343–1347. [PubMed] [Google Scholar]
  30. Peyrat J. P., Bonneterre J., Beuscart R., Djiane J., Demaille A. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res. 1988 Nov 15;48(22):6429–6433. [PubMed] [Google Scholar]
  31. Peyrat J. P., Bonneterre J., Hecquet B., Vennin P., Louchez M. M., Fournier C., Lefebvre J., Demaille A. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer. 1993;29A(4):492–497. doi: 10.1016/s0959-8049(05)80137-6. [DOI] [PubMed] [Google Scholar]
  32. Railo M. J., von Smitten K., Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer. 1994;30A(3):307–311. doi: 10.1016/0959-8049(94)90247-x. [DOI] [PubMed] [Google Scholar]
  33. Reaven G. M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988 Dec;37(12):1595–1607. doi: 10.2337/diab.37.12.1595. [DOI] [PubMed] [Google Scholar]
  34. Ricketts D., Turnbull L., Ryall G., Bakhshi R., Rawson N. S., Gazet J. C., Nolan C., Coombes R. C. Estrogen and progesterone receptors in the normal female breast. Cancer Res. 1991 Apr 1;51(7):1817–1822. [PubMed] [Google Scholar]
  35. Rutanen E. M., Stenman S., Blum W., Kärkkäinen T., Lehtovirta P., Stenman U. H. Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls. J Clin Endocrinol Metab. 1993 Jul;77(1):199–204. doi: 10.1210/jcem.77.1.7686914. [DOI] [PubMed] [Google Scholar]
  36. Singer C., Rasmussen A., Smith H. S., Lippman M. E., Lynch H. T., Cullen K. J. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res. 1995 Jun 1;55(11):2448–2454. [PubMed] [Google Scholar]
  37. Tennant M. K., Thrasher J. B., Twomey P. A., Birnbaum R. S., Plymate S. R. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab. 1996 Jan;81(1):411–420. doi: 10.1210/jcem.81.1.8550786. [DOI] [PubMed] [Google Scholar]
  38. Vishnevsky A. S., Bobrov JuF, Tsyrlina E. V., Dilman V. M. Hyperinsulinemia as a factor modifying sensitivity of endometrial carcinoma to hormonal influences. Eur J Gynaecol Oncol. 1993;14(2):127–130. [PubMed] [Google Scholar]
  39. Westley B. R., May F. E. Role of insulin-like growth factors in steroid modulated proliferation. J Steroid Biochem Mol Biol. 1994 Oct;51(1-2):1–9. doi: 10.1016/0960-0760(94)90109-0. [DOI] [PubMed] [Google Scholar]
  40. Yam D., Ben-Hur H., Fink A., Dgani R., Shani A., Eliraz A., Insler V., Berry E. M. Insulin and glucose status, tissue and plasma lipids in patients with tumours of the ovary or endometrium: possible dietary implications. Br J Cancer. 1994 Dec;70(6):1186–1187. doi: 10.1038/bjc.1994.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Yee D. The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res Treat. 1994;32(1):85–95. doi: 10.1007/BF00666209. [DOI] [PubMed] [Google Scholar]
  42. Yoshikawa T., Noguchi Y., Matsumoto A. Effects of tumor removal and body weight loss on insulin resistance in patients with cancer. Surgery. 1994 Jul;116(1):62–66. [PubMed] [Google Scholar]
  43. Yu H., Levesque M. A., Khosravi M. J., Papanastasiou-Diamandi A., Clark G. M., Diamandis E. P. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer. 1996 Oct;74(8):1242–1247. doi: 10.1038/bjc.1996.523. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES